Although this study was closed early because findings from an unplanned analysis suggested futility, the final analysis did not support that conclusion.
Patients with acute myeloid leukemia and myelodysplastic syndromes reported similar quality of life irrespective of the conditioning regimen the received.
In patients with complete response at transplant, age was found to be the only predictor of clinical outcomes.
Patients receiving treosulfan and fludarabine experienced improved event-free and overall survival compared with patients receiving busulfan and fludarabine.
Approximately one-third of patients in each treatment group experienced symptoms of depression and anxiety during treatment.
Although the 7 + 3 regimen has been the standard of care for acute myeloid leukemia for decades, it may be time to reassess its value and utility.
A retrospective study evaluated the incidence of respiratory adverse events in children and adolescents with AML who received induction chemotherapy.
No active treatment more likely with older age, lower household income, unmarried status, comorbidities.
Over half of patients with TP53-mutated acute myeloid leukemia who received the combination therapy experienced a response.
Median overall survival was 42 months in patients who received sorafenib and 13 months in patients who received chemotherapy alone.
